XML 93 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 28, 2021
Noncontrolling Interest [Line Items]            
Share in net loss of Geneos     $ 0 $ 2,165,213 $ 434,387  
Payments to acquire additional interest in subsidiaries     $ 0 $ 1,999,998 $ 0  
Series A-2 One Preferred Stock            
Noncontrolling Interest [Line Items]            
Share in net loss of Geneos $ 2,200,000          
Investment in Geneos 0          
Resulting in again on memeasurement $ 165,000          
Geneos Therapeutics, Inc.            
Noncontrolling Interest [Line Items]            
Noncontrolling interest, ownership percentage by parent 28.00%   23.00%     35.00%
Geneos Therapeutics, Inc.            
Noncontrolling Interest [Line Items]            
Loss from equity method investment, recorded and allocated to investment   $ (1,500,000)        
Share in net loss of Geneos   434,000        
Investment in Geneos   0        
Geneos Therapeutics, Inc. | Common stock            
Noncontrolling Interest [Line Items]            
Investment in Geneos   0        
Geneos Therapeutics, Inc. | Series A-1 Preferred Stock            
Noncontrolling Interest [Line Items]            
Share in net loss of Geneos   819,000        
Geneos Therapeutics, Inc. | Preferred stock            
Noncontrolling Interest [Line Items]            
Share in net loss of Geneos   4,200,000        
Investment in Geneos   $ 0        
Payments to acquire additional interest in subsidiaries $ 2,000,000